Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 492


Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.

Xu XQ, Wang JM, Gao L, Qiu HY, Chen L, Jia L, Hu XX, Yang JM, Ni X, Chen J, Lü SQ, Zhang WP, Song XM.

Am J Hematol. 2014 Sep;89(9):874-81. doi: 10.1002/ajh.23772.


[Clinical importance of morphological multilineage dysplasia in acute myeloid leukemia with myelodysplasia related changes].

Park SH, Chi HS, Park SJ, Jang S, Park CJ.

Korean J Lab Med. 2010 Jun;30(3):231-8. doi: 10.3343/kjlm.2010.30.3.231. Korean.


Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.

Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, Gotlib J, Zehnder JL, Arber DA.

Blood. 2009 Feb 26;113(9):1906-8. doi: 10.1182/blood-2008-10-182782.


Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).

Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W, Kohlmann A, Klein HU, Vignetti M, Piciocchi A, Fazi P, Martelli MP, Vitale A, Pileri S, Miesner M, Santucci A, Haferlach C, Mandelli F, Haferlach T.

Blood. 2010 May 6;115(18):3776-86. doi: 10.1182/blood-2009-08-240457. Erratum in: Blood. 2010 Aug 12;116(6):1017.


Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.

Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D.

Oncotarget. 2015 Apr 10;6(10):8388-96.


Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.

van der Straaten HM, van Biezen A, Brand R, Schattenberg AV, Egeler RM, Barge RM, Cornelissen JJ, Schouten HC, Ossenkoppele GJ, Verdonck LF; Netherlands Stem Cell Transplant Registry "TYPHON"..

Haematologica. 2005 Oct;90(10):1339-45.


ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.

Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger M, Kern W, Haferlach T.

Genes Chromosomes Cancer. 2012 Apr;51(4):328-37. doi: 10.1002/gcc.21918.


Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.

Bacher U, Schnittger S, Kern W, Weiss T, Haferlach T, Haferlach C.

Ann Hematol. 2009 Dec;88(12):1207-13. doi: 10.1007/s00277-009-0745-3.


Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM)..

Blood. 2010 Nov 11;116(19):3735-42. doi: 10.1182/blood-2010-03-274811.


FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.

Bains A, Luthra R, Medeiros LJ, Zuo Z.

Am J Clin Pathol. 2011 Jan;135(1):62-9. doi: 10.1309/AJCPEI9XU8PYBCIO.


Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.

Patnaik MM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A.

Am J Hematol. 2011 May;86(5):393-8. doi: 10.1002/ajh.21984.


Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA.

Blood. 2003 Jul 1;102(1):43-52.


Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.

Bacher U, Schnittger S, Macijewski K, Grossmann V, Kohlmann A, Alpermann T, Kowarsch A, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Blood. 2012 May 17;119(20):4719-22. doi: 10.1182/blood-2011-12-395574.


Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.

Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W.

J Clin Oncol. 2003 Jan 15;21(2):256-65.


Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification.

Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, Abruzzo LV, Kantarjian HM, Medeiros LJ, Wang SA.

Blood. 2010 Mar 11;115(10):1985-92. doi: 10.1182/blood-2009-09-243964.


Transformation of myelodysplastic syndromes into acute myeloid leukemias.

Shi J, Shao ZH, Liu H, Bai J, Cao YR, He GS, Tu MF, Wang XL, Hao YS, Yang TY, Yang CL.

Chin Med J (Engl). 2004 Jul;117(7):963-7.

Items per page

Supplemental Content

Support Center